GlobeNewswire Inc.··NaOrganogenesis Wins Key Trial for Diabetic Ulcer Treatment, Bolstering PuraPly®AM Case
Organogenesis's PuraPly®AM met primary endpoint in diabetic ulcer trial with statistically significant 12-week wound closure, supporting future insurance coverage expansion.
ORGOregenerative medicinerandomized controlled trial